Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects *ex vivo* in murine intestinal tissue

Frida Fart, Samira Salihović, Aidan McGlinchey, Melanie G. Gareau, Matej Orešič, Jonas Halfvarson, Tuulia Hyötyläinen & Ida Schoultz

Taylor & Francis
Taylor & Francis Group

ORIGINAL ARTICLE

Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects *ex vivo* in murine intestinal tissue

Frida Fart[a], Samira Salihović[a,b], Aidan McGlinchey[a], Melanie G. Gareau[c], Matej Orešič[a,d], Jonas Halfvarson[e]*, Tuulia Hyötyläinen[b]* and Ida Schoultz[a]*

[a]School of Medical Sciences, Örebro University, Örebro, Sweden; [b]School of Science and Technology, Örebro University, Örebro, Sweden; [c]Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis, Davis, CA, USA; [d]Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland; [e]Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

ABSTRACT

Background: Environmental factors are strongly implicated in late-onset of inflammatory bowel disease. Here, we investigate whether high levels of perfluoroalkyl substances are associated with (1) late-onset inflammatory bowel disease, and (2) disturbances of the bile acid pool. We further explore the effect of the specific perfluoroalkyl substance perfluorooctanoic acid on intestinal barrier function in murine tissue.

Methods: Serum levels of perfluoroalkyl substances and bile acids were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole mass spectrometer in matched samples from patients with ulcerative colitis ($n = 20$) and Crohn's disease ($n = 20$) diagnosed at the age of ≥ 55 years. Age and sex-matched blood donors ($n = 20$), were used as healthy controls. *Ex vivo* Ussing chamber experiments were performed to assess the effect of perfluorooctanoic acid on ileal and colonic murine tissue ($n = 9$).

Results: The total amount of perfluoroalkyl substances was significantly increased in patients with ulcerative colitis compared to healthy controls and patients with Crohn's disease ($p < .05$). *Ex vivo* exposure to perfluorooctanoic acid induced a significantly altered ileal and colonic barrier function. The distribution of bile acids, as well as the correlation pattern between (1) perfluoroalkyl substances and (2) bile acids, differed between patient and control groups.

Discussion: Our results demonstrate that perfluoroalkyl substances levels are increased in patients with late-onset ulcerative colitis and may contribute to the disease by inducing a dysfunctional intestinal barrier.

Introduction

Inflammatory bowel disease (IBD), including the two main subtypes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disease of the gastrointestinal tract. The burden of IBD is rising globally, and especially elderly-onset disease is becoming increasingly common [1,2].

The disease is thought to develop as a result of complex interactions between environmental factors, genetic susceptibility and altered gut microbiota. The gut mucosal barrier maintains homeostasis and prevents the entry of pathogenic bacteria and other harmful substances whilst simultaneously absorbing essential nutrients [3]. Some environmental risk factors, such as emulsifiers and heavy metals, may in fact mediate their effects via modulation of the mucosal barrier [4,5]. One of the main chemical groups that humans are exposed to through the diet is perfluoroalkyl substances (PFAS), which are human-made chemicals with a long biological half-life in humans. PFAS have been extensively used since the 1950s, in non-stick cookware and as flame retardants, amongst other uses. Even though the use of some PFAS such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) have been either prohibited or restricted, exposure to these substances still occurs as they, due to their long half-life, remain in the environment. The serum half-life of PFAS varies from two to approximately eight years [6]. Moreover, several of the current substitutes within the PFAS substance class, such as fluorotelomer alcohols, are precursors of several toxic PFAS, including PFOA [7]. An increased incidence of UC has previously been reported in response to high exposure to PFOA through contaminated drinking water in mid-Ohio, United States (U.S) [8]. This observation is supported by findings from animal studies, where PFOA has been reported to alter the immune

---

response and the barrier function via regulation of various cytokines and tight junction proteins [9].

Recently, it has also been shown that PFAS enter the same enterohepatic circulation as bile acids (BAs) and that PFAS may impact the absorption of these BAs in the small intestine [10,11]. The BAs are synthesized from cholesterol in the liver, and these primary BAs are then conjugated either with glycine or taurine, and transported through the biliary system into the small intestine where they can be modified to become secondary BAs by the gut microbiota. Beyond facilitating the digestion and absorption of lipids in the small intestine, BAs possess antibacterial properties, of relevance for the gut mucosal defence, including intestinal permeability [10]. Dysregulation of intestinal BAs has further been implicated in the pathogenesis of IBD [12,13] and *ex vivo* exposure to BAs have been shown to induce an increase in intestinal permeability and bacterial uptake across the colonic mucosa [14].

Current knowledge suggests that late-onset IBD is more linked to environmental risk factors and is associated with a lower genetic risk score, as compared to earlier onset [15]. We, therefore, hypothesised that chronic exposure to PFAS could contribute to the development of late-onset IBD, by altering the intestinal barrier function or indirectly by interfering with the BAs metabolism and, thereby alter the intestinal barrier function. Here we investigate levels of PFAS and their relation to primary and secondary BAs in patients who developed IBD later in life. Moreover, we explore the effect of PFOA, one of the major PFAS, on the intestinal barrier function, by performing *ex vivo* experiments of ileal and colonic murine tissue using the Ussing Chamber.

Materials and methods

Study design

This is a case-control study where serum concentrations of PFAS and BAs were assessed in patients with late-onset IBD, defined as UC or CD diagnosed ≥55 years (cases), and age- and sex-matched blood donors, without any history of chronic gastrointestinal disease, i.e., healthy controls (HC). Comparisons with late-onset CD patients were also stratified for disease location, since BAs are reabsorbed in the terminal ileum. Based on the observed association between exposure to PFOA and late-onset disease, we investigated the effect of PFOA on ileal and colonic barrier function in wild type mice using the Ussing Chamber methodology.

Study population

The samples from IBD patients used in this study were obtained from a previously described cohort [16]. Briefly, patients with CD or UC were consecutively recruited at the outpatient IBD clinic of Örebro University Hospital, Sweden. Blood samples were collected after receiving written informed consent and serum was separated according to standard operating procedures [17], aliquots were stored at −80 °C until further analysis. A diagnosis of IBD was based

Table 1. Clinical characteristics of patients with Crohn's disease (CD) and ulcerative colitis (UC).

	CD n = 20	UC n = 20
Sex (*n*, %)		
Males	13 (65%)	13 (65%)
Females	7 (35%)	7 (35%)
Age at diagnosis (median, IQR)	59 (56–61)	59 (56–61)
Age at sampling (median, IQR)	67 (63–73)	66 (63–74)
Location (CD) (*n*, %)		
Terminal ileum (L1)	11 (55%)	
Colon (L2)	5 (25%)	
Ileocolon (L3)	4 (20%)	
Disease extent (UC) (*n*, %)		
Left-sided		11 (55%)
Extensive		9 (45%)
Behaviour (*n*, %)		
Non-stricturing non-penetrating	8 (40%)	
Stricturing or penetrating	12 (60%)	
Surgery (*n*, %)	13 (65%)	1 (5%)
Ileal-/ileocolonic resection	12 (60%)	
Hemicolectomy	1 (5%)	
Colectomy, ileal-rectum anastomosis		1 (5%)
In clinical remission (*n*, %)*	16 (84%)	14 (70%)
Smoking (*n*, %)		
Current	6 (31.5%)	3 (15%)
Previous	6 (31.5%)	10 (50%)
Never	7 (37%)	7 (35%)

*Information on clinical remission was missing for one CD-patient.

on internationally accepted clinical, endoscopic, radiologic and histologic criteria [18]. The Montreal classification was used for assessment of disease characteristics [19]. Clinical data, including previous IBD-related surgery, were recorded by the treating physician at inclusion. Information on clinical disease acitivity, defined as remission or active disease, was retrospectively collected from the medical notes. A sample set of 20 late-onset UC and 20 late-onset CD patients, whom was diagnosed at age ≥55, matched by age (±5 years), sex and disease duration (±5 years) were selected. Clinical and demographic characteristics of IBD patients included in the study are shown in Table 1. None of the patients were included at disease onset, and blood samples were obtained, at a median of 7 to 8 years after diagnosis.

Analysis of BAs and PFAS

The levels of PFAS and BAs were assessed by ultra-performance liquid chromatography coupled to a triple quadrupole mass spectrometer as previously described [20]. Briefly, all samples were prepared and analysed simultaneously in a randomised order in one batch to minimise potential bias. A positive and negative control, as well as certified reference serum (NIST SRM 1957) were included in the analyses to assess accuracy and consistency.

Ex vivo *Ussing chamber experiments*

The Ussing chamber experiments were performed as described previously [21]. Briefly, segments of distal ileum and proximal colon from adult (6–8 week, *n* = 9) wild type mice (C57BL/6, Jackson Labs, bred in-house at UC Davis, CA, US) were excised. The segments were cut along the mesenteric border and mounted in Ussing chambers (Physiologic

Instruments, San Diego, CA, US), exposing 0.1 cm^2 of tissue area with circulating oxygenated Ringer's buffer (4 ml) maintained at 37 °C. Additionally, glucose (10 mM) was added to the serosal buffer as a source of energy, which was balanced osmotically by mannitol (10 mM) in the mucosal buffer. Agar-salt bridges were used to monitor potential differences across the tissue and to inject the required short-circuit current (Isc) to maintain the potential difference at zero, as registered by an automated voltage clamp. A computer connected to the voltage clamp system recorded Isc and voltage continuously, and the data were analysed using acquisition software (Acquire and Analyze; Physiologic Instruments, San Diego, CA, US). Baseline Isc values (μA/cm^2), indicative of active ion transport, were obtained at equilibrium, approximately 15 min after the tissues were mounted. PFOA (Sigma-Aldrich, San Francisco, CA, US) was added to both the serosal and mucosal side of the chamber in the concentrations of 100 μM and 10 μM at baseline. Conductance (G; mS/cm^2) was used to assess tight junction permeability and mucosal to serosal flux of 4KDa fluorescein isothiocyanate (FITC)-labeled dextran (Sigma-Aldrich) over time (sampled every 30 min for 2 h) was used to assess macromolecular permeability. After completion of the FITC flux measurements, tissues were treated with carbachol (CCh, 10^{-5} μM; Sigma-Aldrich) to assess the stimulated secretory response to PFOA.

Statistical considerations

The majority of PFAS measured were detected in 100% of the participants, however, PFHpA, PFUnDA, PFTrDA were detected in 60, 98 and 97%, respectively, of all participants.

Values that were below the limit of detection, were replaced by values calculated as half of the minimum non-zero value for that compound. Following imputation values were log2 transformed and scaled to zero mean and unit variance. BAs levels could not be ascertained for one CD patients due to error in the analysis and was therefore excluded in further analyses involving BAs.The statistical analyses were performed using IBM SPSS statistics, MetaboAnalyst 4.0 [22] and MetScape 3 for CytoScape [23]. In SPSS, a general linear model was fitted to investigate the associations between PFAS and BAs across the groups, after controlling for confounding factors (age and year at sampling). To show the direction of the change between groups, the data is presented as fold change (i.e., ratio) between CD, UC and HC. Correlation analyses were done using the Spearmann correlation analyses. The Debiased Sparse Partial Correlation algorithm was used for estimating partial correlation networks, as visualised by the MetScape4 version with cut-off values of correlations between ± 0.22 and 0.75. When stratifying for disease location in CD and comparing patients with ileal involvement (L1 and L3) and colonic disease (L2), the Mann–Whitney U analysis was performed, despite the concomitant decrease in sample sizes ($n = 11$ terminal ileum [L1], $n = 5$ colon [L2], $n = 4$ ileum + colon [L3]). For analysis of Ussing Chamber experiments Kruskal-Wallis and the Mann-Whitney U-analysis (GraphPad Prism 8; San Diego, CA, US) was used to assess intestinal permeability, FITC-dextran

passage and stimulated secretory response. Values of $p < .05$ were considered to be statistically significant. The degree of significance for Ussing Chamber experiments were designated as follows: $p < .05$ [*], $p < .01$ [**], non-significant [ns].

Ethical considerations

The Local Ethics Committee approved the study (Dnr: 2006/245), and all patients, as well as, HCs gave their written informed consent. All animal procedures and protocols were approved by UC Davis animal care and use committee (IACUC #2007).

Results

Serum concentrations of PFAS in late-onset UC and CD

The concentrations of PFAS were assessed in serum samples (Table S1). The total level of PFAS ($\sum$PFAS, $p = .03$), PFOS ($p = .03$) and PFOA ($p = .02$) were found to be significantly increased in UC as compared to HC (Table 2). In contrast, the PFAS levels were not significantly different in CD and HC. Similarly, UC had significantly higher levels of $\sum$PFAS ($p = .03$), PFOS ($p = .03$) perfluoroonanoic acid (PFNA, $p = .03$), perfluorodecanoic acid (PFDA, $p = .005$) and perfluoroundecanoic acid (PFUnDA, $p = .03$), as compared to CD.

Ussing chamber experiments

Intestinal permeability was assessed by measuring conductance (G) for tight junction permeability and flux of FITC-dextran as an indicator of macromolecular permeability. Ex vivo exposure of intestinal murine tissue to PFOA at 100 μM resulted in a significant increase in ileal permeability at 60 min compared to baseline. An increased colonic permeability was observed at 60 min after exposure to 10 and 100 μM PFOA compared to baseline. A similar pattern was observed in vehicle, i.e., DMSO without PFOA (Figure 1(a,b)). Exposure to 10 μM PFOA induced an increased flux of FITC-dextran across ileal tissue ($p = .02$). A trend was observed in colonic tissue but was not statistically significant ($p = .06$) (Figure 1(c,d)). Stimulated ion transport across the ileal tissue, assessed by ΔIsc, was not impaired after exposure to PFOA. However, an increased response to CCh after exposure to 10 and 100 μM PFOA was observed across colonic epithelium compared to vehicle (DMSO) (Figure 1(e,f)).

Serum BAs concentrations in UC and CD patients

The concentrations of BAs were assessed in serum samples (Table S1). The distribution of the BAs in the different groups are illustrated in Figure 2. The levels of primary BAs (free and conjugated BAs) were found to be decreased in UC as compared to HC ($p = .02$), as shown in Table 3. At the same time, no differences were observed in secondary BAs or the total level of taurine-conjugated BAs (ΣTBA) and glycine-conjugated BAs (ΣGBA). Primary BAs were decreased in CD as compared to HC ($p = .02$) and UC ($p = .0001$), except for

Table 2. Comparisons of fold change ratio of serum perfluoroalkyl substances (PFAS) concentration in ulcerative colitis (UC), Crohn's disease (CD) and healthy controls (HC) with adjusted *p*-values.

	Fold change UC to HC	UC vs. HC *p*-value	Fold change CD to HC	CD vs. HC *p*-value	Fold change CD to UC	CD vs. UC *p*-value
PFHpA	1.75	.068	1.25	.105	−1.40	.262
PFHxS	1.33	.108	1.26	.790	−1.06	.194
PFOA	2.10	**.023**	1.45	.858	−1.45	.120
PFNA	1.17	.115	−1.33	.973	−1.56	**.027**
PFOS	2.07	**.026**	1.10	.957	−1.88	**.027**
PFDA	1.05	.345	−1.85	.634	−1.95	**.005**
PFUnDA	−1.39	.695	−1.95	.641	−1.40	**.030**
PFTrDA	−1.33	.676	−1.33	.215	1.00	.083
ΣPFAS	2.04	**.028**	1.21	.437	−1.68	**.032**

A negative fold change value represents a decrease in PFAS-levels. Significantly changing PFAS (*p* < .05) are marked in bold. PFHpA: perfluoroheptanoic acid; PFHxS: perfluorohexane sulfonate; PFOA: perfluorooctanoic acid; PFNA: perfluorononanoic acid; PFOS: perfluorooctane sulfonate; PFDA: perfluorodecanoic acid; PFUnDA: perfluoroundecanoic acid; PFTrDA: perfluorotridecanoic acid; ΣPFAS: total PFAS-levels.


Figure 1. The effect of *ex vivo* exposure to perfluorooctanoic acid (PFOA) on intestinal barrier function as measured by conductance, (A) ileal and (B) colonic conductance (G), macromolecular passage as assessed by FITC-dextran flux across (C) ileal mucosa and (D) colonic mucosa and stimulated secretory response to Charbachol, (E) ileal and (F) colonic short circuit current (Isc) after exposure to 10, 100 μM PFOA or vehicle (DMSO). *N* = 7–9. Data are presented as median with range (min/max), significance levels are calculated with Kurskal–Wallis and Mann–Whitney *U*-analysis, (**p* < .05; ***p* < .01; ns: non-significant).

Figure 2. The distribution of individual bile acids (BAs) in ulcerative colitis (UC), Crohn's disease (CD) and healthy controls (HC), grouped as primary conjugated (PRIM., CONJ.), primary free (PRIM., FREE), secondary conjugated (SEC., CONJ.), and secondary free (SEC., FREE).

Table 3. Comparisons of fold change ratio of serum bile acids (BAs) concentration in ulcerative colitis (UC), Crohn's disease (CD) and healthy controls (HC) with adjusted p-values.

BA	Type of BA	Fold change UC to HC	UC vs. HC p-value	Fold change CD to HC	CD vs. HC p-value	Fold change CD to UC	CD vs. UC p-value
CA	Primary (free)	−1.21	.084	1.25	.459	1.51	**.002**
CDCA	Primary (free)	−1.10	**.010**	2.54	**.006**	2.78	**<.001**
TCDCA	Primary taurine-conjugated	−1.65	.184	−7.03	**.002**	−4.26	.080
GCA	Primary glycine-conjugated	−1.88	.052	−2.90	**.013**	−1.54	**.048**
GHDCA	Primary glycine-conjugated	−3.41	.472	−1.69	.827	2.02	.124
GCDCA	Primary glycine-conjugated	−1.49	**.035**	−1.87	.138	−1.26	.044
Tα + βMCA	Secondary taurine-conjugated	−2.05	**.001**	−9.85	**.052**	−4.80	.244
THCA	Secondary taurine-conjugated	−7.62	.468	−160.00	**.002**	−21.00	.166
TDCA	Secondary taurine-conjugated	−1.12	.997	−2.32	.107	−2.08	.112
TLCA	Secondary taurine-conjugated	−1.09	.070	−3.43	**.008**	−3.14	**.023**
GHCA	Secondary glycine-conjugated	−1.99	.128	−2.77	**<.001**	−1.40	.130
GUDCA	Secondary glycine-conjugated	−1.63	.177	−1.29	.165	1.26	.067
GDCA	Secondary glycine-conjugated	−1.81	.151	−2.32	.276	−1.28	.276
GLCA	Secondary glycine-conjugated	−3.10	**.024**	−2.61	**.029**	1.19	.320
UDCA	Secondary	1.25	.650	2.89	**.005**	2.30	**.034**
HDCA	Secondary	1.68	.432	4.10	**.002**	2.44	.009
12-oxoLCA	Secondary	1.22	.265	−1.59	**.048**	−1.94	.114
DCA	Secondary	−1.35	.114	1.43	.541	1.93	.360
LCA	Secondary	1.45	.731	−1.25	.885	−1.81	.500
ΣPrimary BA		−1.67	**.017**	−2.05	**.022**	−1.23	**<.001**
ΣSecondary BA		−1.35	.542	1.59	**.007**	2.14	.065
ΣTaurine conjugated BA		3.37	.366	−4.72	**.002**	−15.89	.095
ΣGlycine conjugated BA		−1.59	.119	−10.26	.089	−6.45	.123

A negative fold change value represents a decrease in BA levels. Significantly changing BA ($p < .05$) are marked in bold. CA: cholic acid; CDCA: chenodeoxycholic acid; TCDCA: taurochenodeoxycholic acid; GCA: glycocholic acid; GHDCA: glycohyodeoxycholic acid; GCDCA: glycochenodeoxycholic acid; Tα + βMCA: taurine-conjugates of α- and β- muricholic acid; THCA: taurohyocholic acid; TDCA: taurodeoxycholic acid: TLCA; taurolitocholic acid; GHCA: glycohyocholic acid; GUDCA; glycoursodeoxycholic acid: GDCA: glycodeoxycholic acid; GLCA: glycolitocholic acid; UDCA: ursodeoxycholic acid; HDCA: hyodeoxycholic acid; 12-oxoLCA: 12-oxo-lithocholic acid; DCA: deoxycholic acid; LCA: lithocholic acid; Σ: total levels.

increased levels of free chenodeoxycholic acid (CDCA) in CD. Moreover, the ratio of the two primary BAs, cholic acid (CA) and CDCA (CA/CDCA) was decreased in CD *vs* HC and UC ($p = .02$), while no difference was observed between UC and HC. The total level of TBA was decreased in CD vs. HC ($p = .003$), while no differences were found in the total level

Table 4. Differences in bile acid (BA) concentrations (ng/mL) in relation to Crohn's disease location, according to Montreal classification.

BA	Type of BA	Ileal involvement (L1, L3) $n = 15$ median (min-max)	Colonic involvement (L2) $n = 5$ median (min-max)	p-Value
CA	Primary (free)	76.05 (7.16 − 231.32)	15.42 (6.69 − 40.59)	**.042**
CDCA	Primary (free)	642.48 (31.18 − 1901.81)	48.68 (16.10 − 114.39)	**.008**
TCDCA	Primary Taurine-conjugated	13.63 (0.90 − 103.87)	38.91 (12.76 − 131.47)	**.042**
GCA	Primary Glycine-conjugated	81.67 (25.48 − 420.87)	109.95 (44.33 − 179.61)	1.000
GHDCA	Primary Glycine-conjugated	4.78 (0.05 − 18.38)	4.22 (2.06 − 16.8)	.672
GCDCA	Primary Glycine-conjugated	354.1 (160.94 − 1393.31)	459.65 (74.90 − 780.92)	.672
Tα + βMCA	Secondary Taurine-conjugated	0.001 (0.001 − 13.61)	2.05 (0.98 − 25.85)	**.002**
THCA	Secondary Taurine-conjugated	0.01 (0.01 − 0.01)	0.76 (0.01 − 1.87)	.053
TDCA	Secondary Taurine-conjugated	5.42 (0.01 − 34.91)	41.6 (11.52 − 74.44)	**.011**
TLCA	Secondary Taurine-conjugated	0.71 (0.01 − 3.70)	3.05 (0.94 − 5.58)	**.019**
GHCA	Secondary Glycine-conjugated	0.95 (0.30 − 3.90)	3.64 (2.21 − 5.79)	**.019**
GUDCA	Secondary Glycine-conjugated	29.38 (2.56 − 257.38)	7.65 (3.40 − 38.72)	.066
GDCA	Secondary Glycine-conjugated	125.66 (0.14 − 731.04)	136.06 (48.46 − 666.84)	.445
GLCA	Secondary Glycine-conjugated	7.06 (0.10 − 95.05)	8.51 (2.49 − 34.72)	.612
UDCA	Secondary	127.7 (9.34 − 963.98)	11.01 (8.65 − 78.71)	**.004**
HDCA	Secondary	604.39 (115.37 − 1781.55)	66.57 (23.09 − 291.09)	**.004**
12-oxoLCA	Secondary	6.69 (0.01 − 138.72)	11.13 (0.01 − 23.57)	.735
DCA	Secondary	507.88 (0.01 − 2888.4)	98.44 (31.21 − 701.53)	.735
LCA	Secondary	11.04 (0.004 − 80.05)	0.004 (0.004 − 15.22)	.445
ΣPrimary BA		1662.7 (343.46 − 3206.9)	714.93 (159.01 − 1169.74)	.197
ΣSecondary BA		1491.19 (131.21 − 5078.7)	329.64 (232.45 − 1834.34)	.119
ΣTaurine conjugated BA		29.72 (0.97 − 109.34)	115.8 (26.96 − 170.99)	**.011**
ΣGlycine conjugated BA		630.09 (235.9 − 2390.45)	1116.8 (184.26 − 1295.45)	.800

Significantly changing BA ($p < .05$) are marked in bold.
CA: cholic acid; CDCA: chenodeoxycholic acid; TCDCA: taurochenodeoxycholic acid; GCA: glycocholic acid; GHDCA: glycohyodeoxycholic acid; GCDCA: glycochenodeoxycholic acid; Tα + βMCA: taurine-conjugates of α- and β- muricholic acid; THCA: taurohyocholic acid; TDCA: taurodeoxycholic acid: TLCA; taurolitocholic acid; GHCA: glycohyocholic acid; GUDCA; glycoursodeoxycholic acid; GDCA: glycodeoxycholic acid; GLCA: glycolitocholic acid; UDCA: ursodeoxycholic acid; HDCA: hyodeoxycholic acid; 12-oxoLCA: 12-oxo-lithocholic acid; DCA: deoxycholic acid; LCA: lithocholic acid; Σ: total levels.

of GBA. The secondary conjugated BAs were found to be increased in CD patients as compared to HC ($p = .007$).

Comparisons of BAs levels were further stratified for disease location in CD according to the Montreal classification (Table 4). Ileal involvement (L1 and L3) was associated with a prominent decrease of $\sum$TBA ($p = .01$) and the glycine-conjugated BA glycohyocholic acid (GHCA, $p = .02$). An increase was observed for both of the free primary BAs (CDCA, $p = .008$ and CA, $p = .04$), the secondary BAs hyodeoxycholic acid (HDCA, $p = .004$) and ursodeoxycholic acid (UDCA, $p = .004$) in patients with ileal involvement (Table 4). The low number of non-resected patients with ileal involvement ($n = 3$) did not allow us to examine the influence of a previous resection among patients with late-onset CD.

Correlations of PFAS and BAs

The total level of PFAS, ($\sum$PFAS) was found to correlate positively with taurohyocholic acid, taurochenodeoxycholic acid (TCDCA) and $\sum$TBA among patients with late-onset UC (Figure 3). In addition, PFOS correlated positively with taurolitocholic acid (TLCA), while PFUnDA correlated positively with taurine-conjugates of α- and β- muricholic acid (Tα + βMCA) among these patients. On the contrary, PFDA showed a negative correlation with CA and TLCA. In CD, the total level of PFAS showed a positive correlation with taurochenodeoxycholic acid (TCDCA), GHCA and $\sum$TBA. PFNA and PFDA also correlated positively with Tα + βMCA. In HCs the correlation pattern was different compared to UC and CD, where

Figure 3. Spearman correlations between perfluoroalkyl substances and bile acids in (A) ulcerative colitis (UC) (B) Crohn's disease (CD) and (C) Healthy controls (HC). Only significant correlations ($p < .05$) are shown.


Figure 4. Partial correlation network projection, i.e., degree of association, of (1) clinical parameters: group (i.e., ulcerative colitis (UC), Crohn's disease (CD) and healthy control (HC)), sampling year, age at sampling and sex, (2) perfluoroalkyl substances (PFAS), (3) primary bile acids (BAs), and (4) secondary BAs. Each node represents a compound (PFAS or BA) or a clinical parameter where each edge represents the strength of the partial correlation between two compounds and/or parameters after conditioning on all other compounds and parameters in the datasets. Edge weights represent the partial correlation coefficients, with blue colour for negative correlations and red colour for positive correlations, the thickness of the line shows the strength of the correlation. Edge ranges adjusted between ± 0.22 to 0.75.

$\sum$PFAS showed a negative correlation to UDCA and positive correlation to TLCA.

Using a Debiased Sparse Partial Correlation algorithm [23], we further estimated partial correlation networks, i.e., the degree of association between the disease-associated BAs, PFAS and clinical parameters (i.e., sampling year, age at sampling and disease (UC and CD) to investigate the impact of sampling year (Figure 4). Positive partial correlations were, particularly, observed between the disease group, PFOA and age at sampling. Thus, further supporting that disease is the major factor influencing the serum levels of PFOA. Of the other clinical parameters, sex was associated with two BAs

(CDCA and glycocholic acid (GCA)) while the sampling year was associated with age at sampling and GLCA and GHCA. Importantly, PFAS showed both negative correlations (glyco-hyodeoxycholic acid (GHDCA), glycoursodeoxycholic acid (GUDCA), HDCA, TDCA) and positive correlations (TLCA, 12-oxo-lithocholic acid (12-oxoLCA), GHCA, hyocholic acid (HCA) and TCDCA) with secondary BAs.

Discussion

Here we investigated the association between serum PFAS levels and late-onset IBD, in relation to the intestinal barrier

function and BA metabolism. Our findings demonstrate that serum PFAS levels, particularly PFOS and PFOA, are increased among late-onset UC patients. Interestingly, our findings were also associated with changes in the BA levels. Our hypothesis of a potential role for PFAS in IBD was further supported by our *ex vivo* study of mouse tissue, where exposure to PFOA resulted in increased ileal and colonic permeability and an enhanced colonic secretory response to CCh. Taken together, these findings may indicate that exposure to PFAS contribute to UC by disrupting the intestinal barrier or indirectly by interfering with the BA metabolism and thereby alter the intestinal barrier function. PFAS have been associated with various adverse health effects, including cancer, liver damage, decreased fertility, and increased risk of chronic inflammatory diseases [24]. Contamination of drinking water with high levels of PFOA, one of the most common PFAS, has also been associated with an increased incidence of UC in the state of Ohio, U.S. [8]. A recent study further showed that mice dosed with PFOA during 10 days displayed an altered expression of tight junction genes in the ileum compared to the colon [9]. These observations indicate that PFAS may play a role in the pathophysiology of IBD and potentially act as an environmental trigger. In the current study, we observed higher PFAS levels among patients with late-onset UC in comparison to HC and CD. Particularly, PFOS and PFOA were at higher levels among patients with UC. This finding is in line with a previous report showing higher levels of PFOA among patients with UC ($n = 116$) [25]. However, a recent population study in Faroe Island failed to show an increased PFAS level in 32 patients with UC and 5 patients with CD [26]. This discrepancy is most likely due to power issues or differences in the geographical exposure to PFAS as outlined by Hammer et al. [26].

Disruption of the intestinal barrier is believed to represent a key disease-mechanism in IBD [27,28]. Given the observed higher levels of PFOA in UC, we investigated the impact of *ex vivo* exposure of PFOA on ileal and colonic barrier function in mice [8,25]. Exposure to PFOA (10 and 100 μM) induced an increased colonic and ileal permeability (G) as well as an increased ion transport across the colonic barrier (Isc) in response to stimulation with CCh. Taken together these data indicate that PFOA have the ability to not only affect the intestinal barrier directly but also decrease the resilience of the colonic barrier. To further support these findings we did observe a significantly increased ileal macromolecular passage after exposure to 10 μM PFOA, but not after exposure to100μM PFOA, compared to vechile. Plausible explanation why we observed significant changes only at the lower exposure level is potentially due to the nonmonotonic response that has been reported in PFAS exposure [29,30]. A non-significant trend towards an increased macromolecular passage was observed across the colonic mucosa. The absence of a significant observation in colon could be due to lack of power. However, previous findings show that mice dosed with PFOA displayed more profound alterations in the ileal expression of genes encoding the tight junction proteins compared to colonic expression

[9]. Hence, potential differences in the effect of PFOA on ileal and colonic mucosa will need to be addressed in future studies. Exposure to DMSO (vehicle) did result in an increased colonic permeability, particularly at 60 min. This is in line with previous findings showing that DMSO does have an effect on the intestinal epithelium and is therefore important to control for [31,32]. Notably, exposure to 100 μM PFOA for 60 min did induce a significantly increased colonic permeability compared to DMSO alone ($p < .05$, data not shown). A recent study, using zonulin as surrogate marker of intestinal permeability stated that there was no significant correlation between exposure to PFAS and zonulin levels among 179 patients/individuals [33], in contrast with our findings. However, the use of zonulin as a potential marker of intestinal permeability have recently been questioned [34,35]. Currently, the Ussing Chamber is the most advanced methodology for investigation of the intestinal barrier function where both the electrophysiology and macropmolecular passage can be monitored. However it is important to acknowledge that our results are based on experiments in a low number of mice and should therefore be interpreted with caution.

Plausible explanation of the changes in the intestinal permeability observed in our study could be linked with the PFOA-induced inhibition of Hepatocyte nuclear factor 4α (HNF4α) [36]), which known to be involved in the formation of tight junctions in the intestinal epithelium. Interestingly, HNF4α mRNA expression is significantly decreased in IBD patients [37] and it also plays a central role in the regulation of BA metabolism in the liver, where it is involved in both the synthesis and the conjugation of primary BAs [38]. Indeed, another potential mechanism via which PFAS exposure may contribute to a dysfunctional intestinal barrier and the pathophysiology of IBD is by affecting the composition of the BA pool [10,39,40]. *In vitro* studies have previously shown that direct exposure of PFAS to a hepatocyte cell line induces strong alterations in the intra- and extracellular BA content with a dose-dependent decrease of intracellular BAs occurring in response to PFAS. In the present paper, we identify significant differences in the circulating levels of BAs in UC and CD as compared to HC. An altered profile of circulating BAs in IBD has been reported previously [12,41,42]. Our results demonstrate that the total level of primary BAs is significantly decreased in UC and CD compared to HC. However, only patients with CD showed increased levels of the free primary CA and CDCA. Previous reports indicate that CDCA, even at low physiological levels (100 μM), has the potential to induce an increased mucosal permeability and bacterial uptake in human colonic tissue [14,43]. Moreover, the decrease in the ratio of CA/CDCA in CD, suggests that the synthesis of BAs is occurring via the alternative BA synthesis route (which usually accounts for only 10% of BA synthesis) and not via the classical pathway in the liver. This, in turn, suggests that CD is associated with a deficiency in the synthesis of BAs via the classical pathway.

The link between PFAS exposure and the composition of the BA pool is supported by the observed correlations between PFAS levels and the altered BA profile. In

accordance with previous literature showing that PFAS suppress the biosynthesis of BAs, we observed negative correlations between the total exposure to PFAS and total levels of primary and secondary BAs [10,39] among HC, with only the secondary BA lithocholic acid and its conjugates (GLCA, TLCA) showing a positive correlation. In addition, IBD patients showed a different profile with positive correlations between total ∑PFAS and ΣTBA. This indicates a possible alteration of the deconjugation in the gut, alternatively an increased absorption of taurine conjugates from the intestine. However, the changes observed in BA content in regard to CD, should be interpreted with caution, as most patients had ileal or ileocolonic CD. Both inflammation and resection of the terminal ileum are known to reduce the reabsorption of BA, and in accordance with previous studies [42,44], ileal CD was associated with an increase of primary BAs (CA and CDCA), an increase of secondary BAs (HDCA and UDCA), and a decrease in ΣTBA. The extent to which these alterations occur due to ongoing inflammation, previous resections, pronounced alterations in the composition and volatility of the gut microbiome or a combination of these could not be examined due to the small sample size [45,46].

The current study has some limitations. First of all, the number of individuals in the study was low and it is therefore important that future research reproduce our findings in larger cohorts. Moreover, the results may have been influenced by previous or ongoing treatments, even though only one CD patient was prescribed BA sequestrants.

Secondly, the HC group was slightly younger (mean age: 59) than the patients with IBD, and their serum samples were obtained a few years later. However, possible confounding effects of age and year of sampling were accounted for in our statistical analysis and should not have any major impact on the results. Nevertheless, future studies should validate these results in a larger cohort, where samples from cases and controls are obtained within an identical period. Additionally, we were not able to relate our findings to the composition of gut microbiota, since stool samples were not available. Future studies should investigate this as recent evidence indicate that PFAS can directly affect the gut microbiota composition. In the present study, we selectively included patients with late-onset IBD, based on the hypothesis that exposure to environmental risk factors is more important among these patients. The extent to which our findings can be generalised to patients with younger onset IBD is unknown. There is also a need to validate the observed effects on the intestinal barrier in response to exposure to PFOA in functional studies using a larger sample of mice and mucosal samples from patients with IBD. In conclusion, our study demonstrates that total levels of PFAS are significantly increased in patients with late-onset UC compared to HC and patients with CD and correlate with disturbances in the BA pool. Moreover, we propose that a possible mechanism through which PFAS contribute to the pathophysiology of UC is via disrupting the intestinal barrier or indirectly by interfering with the BAs metabolism and that this subsequently contribute to an altered intestinal barrier function.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author, [IS], upon reasonable request.

References

[1] Everhov ÅH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3): 518–528.

[2] GBD 2017 Inflammatory Bowel Disease CollaboratorsThe global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.

[3] Schoultz I, Keita ÅV. The intestinal barrier and current techniques for the assessment of gut permeability. Cells. 2020;9(8):1909.

[4] Roberts CL, Keita AV, Duncan SH, et al. Translocation of crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. 2010;59(10):1331–1339.

[5] Nair N, Austin C, Curtin P, et al. Association between early-life exposures and inflammatory bowel diseases, based on analyses of deciduous teeth. Gastroenterology. 2020;159(1):383–387.

[6] Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9):1298–1305.

[7] Huang MC, Robinson VG, Waidyanatha S, et al. Toxicokinetics of 8:2 fluorotelomer alcohol (8:2-FTOH) in male and female hsd:Sprague dawley SD rats after intravenous and gavage administration. Toxicol Rep. 2019;6:924–932.

[8] Steenland K, Zhao L, Winquist A, et al. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. Environ. Health Perspect. 2013;121(8):900–905.

[9] Rashid F, Ahmad S, Irudayaraj JMK. Effect of perfluorooctanoic acid on the epigenetic and tight junction genes of the mouse intestine. Toxics. 2020;8(3):64.

[10] Zhao W, Zitzow JD, Ehresman DJ, et al. Na+/taurocholate cotransporting polypeptide and apical Sodium-Dependent bile acid transporter are involved in the disposition of perfluoroalkyl sulfonates in humans and rats. Toxicol Sci. 2015;146(2):363–373.

[11] Chiang JY. Recent advances in understanding bile acid homeostasis. F1000Res. 2017;6:2029–2028.

[12] Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539.

[13] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–237.

[14] Münch A, Ström M, Söderholm JD. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol. 2007;42(10):1167–1174.

[15] Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148(6):1087–1106.

[16] Fransén K, Franzén P, Magnuson A, et al. Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of crohn's disease. PLoS One. 2013;8(8):e72739–6.

[17] Drobin K, Assadi G, Hong M-G, et al. Targeted analysis of serum proteins encoded at known inflammatory bowel disease risk loci. Inflamm. Bowel Dis. 2019;25(2):306–316.

[18] Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.

[19] Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005; 19(Suppl A):5A–36A.

[20] Salihović S, Dickens AM, Schoultz I, et al. Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2020;412(10):2251–2259.

[21] Pusceddu MM, Barboza M, Keogh CE, et al. Nod-like receptors are critical for gut-brain axis signalling in mice. J Physiol. 2019; 597(24):5777–5797.

[22] Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics. 2019;68(1):1–128.

[23] Basu S, Duren W, Evans CR, et al. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. Bioinformatics. 2017;33(10):1545–1553.

[24] Sunderland EM, Hu XC, Dassuncao C, et al. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J Expo Sci Environ Epidemiol. 2019;29(2):131–147.

[25] Steenland K, Kugathasan S, Barr DB. PFOA and ulcerative colitis. Environ Res. 2018;165:317–321.

[26] Hammer T, Lophaven SN, Nielsen KR, et al. Dietary risk factors for inflammatory bowel diseases in a high-risk population: results from the faroese IBD study. United European Gastroenterol J. 2019;7(7):924–932.

[27] Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17(1):362–381.

[28] Schoultz I, Keita ÅV. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. Cells. 2019;8(2):193.

[29] Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, et al. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS One. 2013;8(2):e56969.

[30] Steenland K, Tinker S, Frisbee S, et al. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009; 170(10):1268–1278.

[31] Da Violante G, Zerrouk N, Richard I, et al. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. Biol Pharm Bullet. 2002;25(12):1600–1603.

[32] Hollebeeck S, Raas T, Piront N, et al. Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal caco-2 cell model. Toxicol Lett. 2011;206(3):268–275.

[33] Xu Y, Li Y, Scott K, et al. Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water. Environ. Res. 2020;181:108923–108928.

[34] Ajamian M, Steer D, Rosella G, et al. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLOS One. 2019;14(1):e0210728–10.

[35] Meira de-Faria F, Bednarska O, Ström M, et al. Colonic paracellular permeability and circulating zonulin-related proteins. Scand J Gastroenterol. 2021;56(4):424–431.

[36] Scharmach E, Buhrke T, Lichtenstein D, et al. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). Toxicol Lett. 2012;212(2):106–112.

[37] Ahn S-H, Shah YM, Inoue J, et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(7):908–920.

[38] Chiang JYL. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5(2):137–147.

[39] Bijland S, Rensen PCN, Pieterman EJ, et al. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicol Sci. 2011;123(1):290–303.

[40] Behr A-C, Kwiatkowski A, Ståhlman M, et al. Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. Arch Toxicol. 2020;94(5):1673–1686.

[41] Ejderhamn J, Strandvik B. Serum bile acids in relation to disease activity and intake of dietary fibers in juvenile ulcerative colitis. Digestion. 1991;50(3-4):162–169.

[42] Gnewuch C, Liebisch G, Langmann T, et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol. 2009;15(25):3134–3141.

[43] Münch A, Söderholm JD, Ost A, et al. Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. Aliment Pharmacol Ther. 2011; 33(8):954–960.

[44] Meihoff WE, Kern F. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest. 1968;47(2): 261–267.

[45] Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2(5):1–9.

[46] Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel Dis. 2011;17(6):1322–1327.